Abstract
The development of siRNA technology has provided new opportunities for
gene-specific inhibition and knockdown, as well as new ideas for the
treatment of disease. Four siRNA drugs have already been approved for
marketing. However, the instability of siRNA in vivo makes systemic
delivery ineffective. Inhaled siRNA formulations can deliver drugs
directly to the lung, showing great potential for treating respiratory
diseases. The clinical applications of inhaled siRNA formulations still
face challenges because effective delivery of siRNA to the lung requires
overcoming the pulmonary and cellular barriers. This paper reviews the
research progress for siRNA inhalation formulations for the treatment of
various respiratory diseases and summarizes the chemical structural
modifications and the various delivery systems for siRNA. Finally, we
conclude the latest clinical application research for inhaled siRNA
formulations and discuss the potential difficulty in efficient clinical
application.
| Original language | English |
|---|---|
| Article number | 1193 |
| Number of pages | 27 |
| Journal | Pharmaceutics |
| Volume | 14 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2 Jun 2022 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
User-Defined Keywords
- clinical application
- delivery systems
- drug delivery barriers
- inhaled siRNA formulations
- respiratory diseases
- structural modification
Fingerprint
Dive into the research topics of 'Inhaled siRNA Formulations for Respiratory Diseases: From Basic Research to Clinical Application'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver